timothy sykes logo
BHC Stock Surges After Earnings Beat And Raised 2026 Outlook Thumbnail
G Google News

BHC Stock Surges After Earnings Beat And Raised 2026 Outlook

TIM SYKES•UPDATED AUG. 1, 2026, 10:07 AM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Bausch Health Companies Inc. stocks have been trading up by 13.62 percent amid strong optimism over its debt-reduction progress.

What Traders Need To Know

  • Q2 non-GAAP EPS of $1.26 vs. $1.01 and revenue of $2.85B vs. $2.66B extended Bausch Health Companies Inc.’s streak to 13 straight quarters of revenue and adjusted EBITDA growth.
  • Strong adjusted operating cash flow and notable net debt reduction improved BHC’s financial flexibility, a key point for a leveraged specialty pharma name.
  • 2026 guidance calls for $10.79B–$11.04B in revenue and $4.05B–$4.175B in adjusted EBITDA, modestly above Street expectations.
  • Shares of BHC jumped roughly 26%–27% after the Q2 beat and raised 2026 outlook, signaling a sharp sentiment shift.
  • RBC Capital had held a Sector Perform rating with a $9 target around $4.54 ahead of Q2, while still flagging Xifaxan litigation, Bausch + Lomb monetization, and FX as overhangs.

Candlestick Chart

Weekly Update Jul 27 – Jul 31, 2026: On Saturday, August 01, 2026 Bausch Health Companies Inc. stock [NYSE: BHC] is trending up by 13.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Bausch Health holds a subscale but improving position in specialty pharma, with Q2 revenue of $2.85B and trailing annual revenue of ~$10.3B growing mid‑single to high‑single digits. Gross margin is strong at 71% and EBITDA margin near 19%, but consolidated pretax and net margins remain negative, reflected in ROA of about ‑2% and heavily negative equity from past write‑downs. Leverage is extreme (long‑term debt ~$19.9B, interest coverage only 1.2x), yet Q2 free cash flow of $593M and operating cash flow of $670M materially de‑risk near‑term liquidity.

Technically, BHC has undergone a violent repricing: the weekly range jumped from ~$4.50 to an intraday high above $7, with the latest close around $6.85 following a 25–30% earnings‑driven gap. Five‑minute candles show sustained bid and elevated volume near $6.50–$6.80, confirming new institutional interest and a bullish short‑covering dynamic. The dominant trend is now firmly up; the key actionable level is $6.50 support — above it, momentum buyers can target a retest of $7.25–$7.50.

Fundamentally, the Q2 beat and raised 2026 guidance (revenue $10.79–$11.04B; adjusted EBITDA $4.05–$4.175B) put Bausch ahead of broader Healthcare and Pharma peers on growth, but still behind on balance‑sheet quality and legal risk given Xifaxan IP litigation and elevated leverage. Relative to a depressed ~$6.85 price and a $9 Street target, risk‑reward is now favorable. I set a decisive 12‑month target of $9, with key support at $6.50 and resistance at $9–$9.50.

More Breaking News

Quick Financial Overview

Bausch Health Companies Inc. (BHC) just delivered a clean beat where it mattered for traders: earnings, revenue, and guidance. Q2 non-GAAP EPS of $1.26 versus $1.01 and revenue of $2.85B versus $2.66B confirmed solid operating momentum and marked the 13th straight quarter of year-over-year revenue and adjusted EBITDA growth, excluding Bausch + Lomb. Profitability remains mixed at the bottom line, with an EBIT margin near 7% and a negative net profit margin, but the gross margin around 71% shows strong pricing power in the portfolio.

The balance sheet is still heavy, with about $19.88B in long-term debt and stockholders’ equity of roughly -$1.77B, but BHC is clearly using cash flow to chip away at leverage. Operating cash flow near $670M and free cash flow around $593M for the recent quarter support the narrative of improving financial flexibility, backed by an interest coverage ratio around 1.2 and a current ratio of 1.3. Management’s 2026 guidance of $10.79B–$11.04B in revenue and $4.05B–$4.175B in adjusted EBITDA suggests steady growth from the current annual revenue run-rate of about $10.27B.

On the tape, the reaction has been explosive. The weekly data show BHC grinding in the mid-$4s early in the week, then spiking from a $4.88 close to above $6, and finishing near $6.85 by 2026/07/31. That is consistent with the reported 26%–27% surge after the report and guidance. Intraday, a 5-minute snapshot around the move shows price pushing from about $6 toward an intraday high near $6.92 before closing just under that, a strong trend day that signals aggressive buying and likely short covering.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”